Top25-SA-Banner

Analysts Have Conflicting Sentiments on These Healthcare Companies: ObsEva SA (OBSV), PTC Therapeutics (PTCT) and Mallinckrodt (MNK)


Analysts have been eager to weigh in on the Healthcare sector with new ratings on ObsEva SA (NASDAQ:OBSV), PTC Therapeutics (NASDAQ:PTCT) and Mallinckrodt (NYSE:MNK).

ObsEva SA (OBSV)

In a report released yesterday, Liana Moussatos from Wedbush reiterated a Buy rating on ObsEva SA, with a price target of $34. The company’s shares opened today at $17.45.

According to TipRanks.com, Moussatos is a 1-star analyst with an average return of -0.9% and a 41.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Global Blood Therapeutics.

Currently, the analyst consensus on ObsEva SA is a Strong Buy with an average price target of $33.75, which is a 93.4% upside from current levels. In a report issued on September 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $44 price target.

.

See today’s analyst top recommended stocks >>

PTC Therapeutics (PTCT)

In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Hold rating on PTC Therapeutics. The company’s shares opened today at $44.99.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 30.0% and a 52.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on PTC Therapeutics is a Moderate Buy with an average price target of $52.33, implying a 16.3% upside from current levels. In a report released yesterday, Merrill Lynch also upgraded the stock to Hold with a $49 price target.

.

Mallinckrodt (MNK)

In a report released today, Irina Rivkind Koffler from Mizuho Securities maintained a Hold rating on Mallinckrodt, with a price target of $30. The company’s shares opened today at $29.74.

Rivkind Koffler commented:

“We model a slight increase to $296.1M in 3Q:18, but note that FactSet consensus is currently $277.8M, setting up the quarter for a potential beat. Because Mallinckrodt is not planning to disclose its VTS-270 data before late November/December, we believe the quarter has been generally de-risked after this Praxair announcement.”

According to TipRanks.com, Koffler is a 4-star analyst with an average return of 10.5% and a 46.3% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Supernus Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Mallinckrodt with a $32 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.